In accordance with the provisions outlined in the Public Health Act, 2012 (Act 851), the Food and Drugs Authority (FDA) is urgently calling upon all stakeholders involved in the salt value chain to immediately regularize their operations with the Authority. This directive aims to safeguard the public from Iodine Deficiency Disorders.
Key Provisions and Requirements
- Iodization Mandate: Section 107 of Act 851 mandates that all salt intended for human and animal consumption must be iodized as per the specifications outlined in GS 154:2017, titled “Spices and Condiments-Specification of Salt Fortified with Iodine.”
2. Licensing Obligation: Section 130 of Act 851 stipulates that all salt-producing and manufacturing facilities must be licensed.
3. Registration of Packaged Salt: Section 97 requires that all packaged salt be registered with the FDA before being introduced to the market.
4. Transportation Permits: Section 107(6)(c) specifies that salt for industrial purposes should not be transported without a permit issued by the FDA.
Market surveillance conducted in 2023 revealed significant non-compliances, especially among producers of non-prepackaged or unpackaged rock salt. These non-compliances include:
Structural and Operational Deficiencies: Production facilities were found to have structural and operational deficiencies that could compromise the safety and quality of the final product.
Non-Iodization: Salt in trade was found not to be iodized as required by law, contravening Sections 97 and 107 of Act 851.
The FDA emphasizes that the non-iodization of edible salt is a major violation and poses a significant public health concern. Iodine deficiency can lead to severe consequences such as stillbirths, congenital defects, decreased cognitive capacity, infant mortality, delayed physical development, and goiter in both humans and animals.
All artisanal salt producer associations, artisanal salt producers, large-scale salt manufacturers, salt storage facility operators, salt transporters, and retailers are hereby notified to promptly regularize their operations with the FDA. Operators of artisanal salt facilities are encouraged to contact the nearest FDA Office in their respective regions or districts for further information and technical assistance.
The public is cautioned that violations of salt iodization provisions in Act 851 will be met with prosecution.
The FDA remains committed to upholding public health standards and ensuring the safety and quality of salt products available in the market.
About The Author
